TFFP - TFF Pharmaceuticals selects lead monoclonal antibody to treat COVID-19

TFF Pharmaceuticals (TFFP) and Augmenta Bioworks announces that AUG-3387 has been selected as the first lead monoclonal antibody for clinical development against COVID-19 under their Joint Development and Collaboration Agreement.Targeting the SARS-Cov2 spike protein, AUG-3387 was isolated from an asymptomatic patient and then identified through Augmenta’s platform in less than two weeks.The company highlighted that in in-vitro preclinical testing, AUG-3387 effectively neutralizes SARS-CoV2 and has demonstrated activity against all variant strains tested to date, including the major COVID variants of concern."We look forward to continued scale up manufacturing, completion of toxicology studies and enablement of human clinical trials in the coming months," Glenn Mattes, Chief Executive Officer of TFF Pharmaceuticals said.

For further details see:

TFF Pharmaceuticals selects lead monoclonal antibody to treat COVID-19